NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.20
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.20
Open2.26
Bid2.18 x 2200
Ask2.23 x 1300
Day's Range2.15 - 2.27
52 Week Range2.00 - 168.00
Volume762,227
Avg. Volume1,074,082
Market Cap42.623M
Beta (3Y Monthly)2.27
PE Ratio (TTM)N/A
EPS (TTM)-0.17
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.88
Trade prices are not sourced from all markets
  • CNW Group5 days ago

    Neovasc Announces Publication of a Peer-Reviewed Article on Tiara™ Cases in Circulation: Cardiovascular Interventions

    VANCOUVER , Oct. 16, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that an original article was published in Circulation: Cardiovascular Interventions titled 'Transcatheter Mitral Valve Replacement in Patients With Previous Aortic Valve Replacement', which reports for the first time ever the experience of transcatheter mitral valve replacement ("TMVR") using Neovasc's Tiara™ ("Tiara") valve in patients with previous aortic valve replacement. The Tiara is a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation ("MR"), one of the most prevalent valvular heart diseases in western countries.  Tiara is not currently approved for commercial sale in any geographies.

  • PR Newswire5 days ago

    Neovasc Announces Publication of a Peer-Reviewed Article on Tiara™ Cases in Circulation: Cardiovascular Interventions

    VANCOUVER, Oct. 16, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that an original article was published in Circulation: Cardiovascular Interventions titled 'Transcatheter Mitral Valve Replacement in Patients With Previous Aortic Valve Replacement', which reports for the first time ever the experience of transcatheter mitral valve replacement ("TMVR") using Neovasc's Tiara™ ("Tiara") valve in patients with previous aortic valve replacement. The Tiara is a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation ("MR"), one of the most prevalent valvular heart diseases in western countries.  Tiara is not currently approved for commercial sale in any geographies.

  • ACCESSWIRE10 days ago

    Today’s Research Reports on Stocks to Watch: Neovasc and AcelRx Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 11, 2018 / Neovasc Inc. shares and AcelRx Pharmaceuticals shares were both winning big in Wedneday’s session on positive FDA developments. Neovasc headed higher on news that the FDA has granted Breakthrough Device designation to the Neovasc Reducer™. AcelRx Pharmaceuticals jumped after FDA staff had said the company's opioid painkiller was safe and effective for use based on resubmitted data.

  • Why Neovasc Stock (NVCN) Is Skyrocketing Today
    InvestorPlace11 days ago

    Why Neovasc Stock (NVCN) Is Skyrocketing Today

    Neovasc stock (NASDAQ:NVCN) is skyrocketing more than 26% on Wednesday as the company received good news from the U.S. Food and Drug Administration (FDA) regarding one of its latest products. The medical device company revealed that its Neovasc Reducer device that was designed to treat refractory angina was granted a Breakthrough Device designation by the FDA. The news caused Neovasc stock to skyrocket with volume soaring up to 21.2 million shares, which is considerably higher than the stock’s full-day average of just under 800,000 shares.

  • MarketWatch11 days ago

    Neovasc's stock rockets after 'Reducer' granted Breakthrough Device designation

    Shares of Neovasc Inc. shot up 37% to pace the Nasdaq's gainers in morning trade Wednesday, after the medical device company said it Neovasc Reducer device for the treatment of refactory angina was granted a Breakthrough Device designation by the Food and Drug Administration. Volume spiked up to 21.2 million shares, compared with the full-day average of just under 800,000 shares. Breakthrough Device designation allows for expedited development and review of a device that demonstrates "compelling potential" to provide more effective treatment for life-threatening diseases. "We will now start a process of further discussions and filings with the FDA, to obtain further guidance as to the regulatory pathway for entrance into the U.S. market," said Chief Executive Fred Colen. The stock has still plunged 94% year to date, while the S&P 500 has gained 6.6%.

  • PR Newswire11 days ago

    Neovasc Reducer™ Granted Breakthrough Device Designation from FDA

    VANCOUVER, Oct. 10, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Breakthrough Device designation to the Neovasc Reducer™ (the "Reducer"), a medical device for the treatment of refractory angina, which is not currently approved for commercial sale in the U.S. The FDA grants Breakthrough Device designation in order to expedite the development and review of a device that demonstrates compelling potential to provide a more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases.

  • CNW Group11 days ago

    Neovasc Reducer™ Granted Breakthrough Device Designation from FDA

    VANCOUVER , Oct. 10, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Breakthrough Device designation to the Neovasc Reducer™ (the "Reducer"), a medical device for the treatment of refractory angina, which is not currently approved for commercial sale in the U.S. The FDA grants Breakthrough Device designation in order to expedite the development and review of a device that demonstrates compelling potential to provide a more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases.

  • PR Newswire12 days ago

    Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

    VANCOUVER, Oct. 9, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has received written notification from the Nasdaq Hearings Panel (the "Panel") notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the "Nasdaq"), that it is in compliance with all other applicable continued listing requirements and that the Panel has determined to continue the listing of the Company's common shares on the Nasdaq. Words and phrases such as "continue", "may", "will" and "growing", and similar words or expressions, are intended to identify these forward-looking statements.

  • CNW Group12 days ago

    Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

    VANCOUVER , Oct. 9, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has received written notification from the Nasdaq Hearings Panel (the "Panel") notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the "Nasdaq"), that it is in compliance with all other applicable continued listing requirements and that the Panel has determined to continue the listing of the Company's common shares on the Nasdaq. Words and phrases such as "continue", "may", "will" and "growing", and similar words or expressions, are intended to identify these forward-looking statements.

  • MarketWatch18 days ago

    Neovasc shares soar 24% on news of positive data from first U.S. patient to use device to treat angina

    Neovasc Inc. shares soared more than 24% in premarket trade Wednesday, after the company announced positive data from the first U.S. patient to be implanted with a device to treat refractory angina. The Vancouver-based medical device company said its Neovasc Reducer produced positive data in a 12-week follow-up on the patient, who was able to walk several miles without symptoms and greatly reduce his use of nitroglycerin. Prior to using the device, the patient could walk only two blocks before experiencing angina and used nitroglycerin two to three times a week. The device has already achieved positive results in European studies, according to Chief Executive Fred Colen. Refractory angina affects 600,000 to 1.8 million Americans with up to 100,000 new cases emerging every year. Neovasc shares have fallen 96% in 2018 through Tuesday, while the S&P 500 has gained 9%.

  • PR Newswire18 days ago

    Neovasc Announces Positive 12-week Follow-up Data from the First U.S. Patient Implanted with a Neovasc Reducer™

    VANCOUVER, Oct. 3, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced positive 12-week follow-up data from the first U.S. patient implanted with a Neovasc Reducer™ (the "Reducer"), a CE-Marked medical device for the treatment of refractory angina. It affects millions of patients worldwide, who typically lead severely restricted lives as a result of their disabling symptoms, and its incidence is growing.

  • CNW Group18 days ago

    Neovasc Announces Positive 12-week Follow-up Data from the First U.S. Patient Implanted with a Neovasc Reducer™

    VANCOUVER , Oct. 3, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced positive 12-week follow-up data from the first U.S. patient implanted with a Neovasc Reducer™ (the "Reducer"), a CE-Marked medical device for the treatment of refractory angina. The Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies.

  • Neovasc (NVCN) Looks Good: Stock Adds 7.4% in Session
    Zacks24 days ago

    Neovasc (NVCN) Looks Good: Stock Adds 7.4% in Session

    Neovasc (NVCN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • ACCESSWIRE27 days ago

    Today's Research Reports on Trending Tickers: TransEnterix and Neovasc

    NEW YORK, NY / ACCESSWIRE / September 24, 2018 / U.S. markets were mixed on Friday, with the Dow Jones managing to close at an all-time high despite a plunge in technology and internet stocks. The Dow Jones Industrial Average gained 0.32 percent to close at 26,743.50, while the S&P 500 Index declined 0.04 percent to close at 2,929.67.

  • CNW Grouplast month

    Neovasc's Tiara and Reducer to be Featured at TCT 2018 Conference

    VANCOUVER , Sept. 20, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that its Tiara™ ("Tiara"), a transcatheter treatment of mitral valve disease, and the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device used for the treatment of refractory angina, will both be featured in several presentations at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 scientific symposium to take place September 21-25, 2018 in San Diego, California .

  • PR Newswirelast month

    Neovasc's Tiara and Reducer to be Featured at TCT 2018 Conference

    VANCOUVER, Sept. 20, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that its Tiara™ ("Tiara"), a transcatheter treatment of mitral valve disease, and the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device used for the treatment of refractory angina, will both be featured in several presentations at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 scientific symposium to take place September 21-25, 2018 in San Diego, California.

  • PR Newswirelast month

    Neovasc Announces 100th Patient to Receive Reducer Therapy in Germany

    VANCOUVER, Sept. 19, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that a Neovasc Reducer™ (the "Reducer") has now been implanted in 100 patients in Germany. The Reducer is a wire mesh implanted into a vein in the heart which treats patients with refractory angina. A growing number of patients suffer from significant angina despite optimal medication and prior revascularisations (via percutaneous coronary intervention or coronary artery bypass graft), or when revascularization is not feasible or when the risks is too great.

  • CNW Grouplast month

    Neovasc Announces 100th Patient to Receive Reducer Therapy in Germany

    VANCOUVER , Sept. 19, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that a Neovasc Reducer™ (the "Reducer") has now been implanted in 100 patients in Germany . The Reducer is a wire mesh implanted into a vein in the heart which treats patients with refractory angina. A growing number of patients suffer from significant angina despite optimal medication and prior revascularisations (via percutaneous coronary intervention or coronary artery bypass graft), or when revascularization is not feasible or when the risks is too great.

  • PR Newswirelast month

    Neovasc Announces Effective Date of Share Consolidation

    NASDAQ, TSX: NVCN VANCOUVER , Sept. 18, 2018 /PRNewswire/ - Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive ...

  • CNW Grouplast month

    Neovasc Announces Effective Date of Share Consolidation

    Neovasc Announces Effective Date of Share Consolidation

  • PR Newswirelast month

    Neovasc Announces Amendments to Outstanding Convertible Notes, including 1-Year Extension of Note Maturity Date

    VANCOUVER, Sept. 12, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the holders ("Holders") of its senior secured convertible notes (the "Notes") have agreed to amend certain terms of the Notes and other concessions, including a one-year extension of the maturity of the Notes from May 17, 2019 until May 17, 2020. Most importantly, the extension of the expiration date for the convertible debt by one year will provide the Company with greater flexibility for repayment of the debt, and while no predictions can be made as to conversions, this extension may ease the pressure on the conversions," commented Fred Colen, Neovasc's President and Chief Executive Officer.

  • CNW Grouplast month

    Neovasc Announces Amendments to Outstanding Convertible Notes, including 1-Year Extension of Note Maturity Date

    VANCOUVER , Sept. 12, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the holders ("Holders") of its senior secured convertible notes (the "Notes") have agreed to amend certain terms of the Notes and other concessions, including a one-year extension of the maturity of the Notes from May 17, 2019 until May 17, 2020 . Most importantly, the extension of the expiration date for the convertible debt by one year will provide the Company with greater flexibility for repayment of the debt, and while no predictions can be made as to conversions, this extension may ease the pressure on the conversions," commented Fred Colen , Neovasc's President and Chief Executive Officer.

  • PR Newswirelast month

    Neovasc Announces Extension to Regain Compliance with Nasdaq Minimum Bid Price Rule

    VANCOUVER, Sept. 11, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today (1) that it has received the decision of the Nasdaq Hearings Panel (the "Panel") to grant it a extension until October 15, 2018 to regain compliance with the US$1.00 minimum bid price requirement and (2) the Company's plans to execute the reverse stock split (share consolidation), approved at its Annual General and Special Meeting of Shareholders on June 4, 2018. The Nasdaq Stock Market LLC ("Nasdaq") held an oral hearing on August 30, 2018, at which the Panel considered Neovasc's appeal of the Nasdaq Listing Qualifications Staff (the "Staff") decision to delist the Company's common shares (the "Common Shares") from the Nasdaq Capital Market for non-compliance with the US$1.00 minimum bid price requirement.

  • CNW Grouplast month

    Neovasc Announces Extension to Regain Compliance with Nasdaq Minimum Bid Price Rule

    VANCOUVER , Sept. 11, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today (1) that it has received the decision of the Nasdaq Hearings Panel (the "Panel") to grant it a extension until October 15, 2018 to regain compliance with the US$1.00 minimum bid price requirement and (2) the Company's plans to execute the reverse stock split (share consolidation), approved at its Annual General and Special Meeting of Shareholders on June 4, 2018 . The Nasdaq Stock Market LLC ("Nasdaq") held an oral hearing on August 30, 2018 , at which the Panel considered Neovasc's appeal of the Nasdaq Listing Qualifications Staff (the "Staff") decision to delist the Company's common shares (the "Common Shares") from the Nasdaq Capital Market for non-compliance with the US$1.00 minimum bid price requirement.

  • CNW Grouplast month

    Neovasc Provides Initial Comments on Lawsuit

    VANCOUVER , Sept. 11, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, has been made aware of a lawsuit filed by Endovalve Inc. and Micro Interventional Devices, Inc. (the "Plaintiffs") in the U.S. District Court for the District of New Jersey including certain allegations relating to Neovasc's transcatheter mitral valve technology, including the Tiara™ ("Tiara") device. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws regarding the Company's plans and expectations concerning the lawsuit filed against the Company, the Company's intention to defend itself vigorously, and the growing cardiovascular marketplace.